Vasodilatory shock is the most common type of shock. Catecholamine vasopressors are the cornerstone of hemodynamic therapy but carry risks. Angiotensin II (AT2) was recently approved, and other novel agents (selepressin and terlipressin) are under investigation and used outside the United States (terlipressin). We performed a systematic review to summarize the efficacy and safety of these novel vasopressors and to offer guidance on their appropriate use.
Design:
Systematic review of controlled trials.
Methods:
Numerous databases were searched using terms related to angiotensin II, selepressin, terlipressin, vasopressor, and shock. Twenty-one citations, including 16 prospective comparative trials and 5 post hoc analyses reporting effects of AT2, selepressin, and terlipressin, were reviewed for data on outcomes related to hemodynamic measures, mortality, severity and duration of illness, concomitant vasopressor utilization, and adverse effects. Findings from eligible literature are described qualitatively using Cochrane methods.
Results:
Fourteen controlled trials were assessed after exclusion of 2 dated trials of a distinct AT2 formulation. Trials are limited for AT2 (n = 2) and selepressin (n = 1), while terlipressin was investigated in 11 small trials. Overall, the trials have an unclear risk of bias. Most report mean arterial pressure (MAP) as primary end point, and all indicate novel vasopressors increase MAP compared to placebo and to a similar degree as with catecholamine vasopressors. Mortality findings are preliminary, as they have been limited to specific subgroups in trials of terlipressin and post hoc analyses of one trial of AT2. Trials reported safety concerns for each agent including thromboembolism with AT2 and ischemia with terlipressin/selepressin.
Conclusion:
In this systematic review, controlled trials of novel vasopressors in treatment of vasodilatory shock were limited and of low quality. Angiotensin II, selepressin, and terlipressin appear to significantly increase MAP, but further study is required, particularly for selepressin, to determine their safety, efficacy, and role in treatment of vasodilatory shock.
VincentJLDe BackerD. Circulatory shock. N Engl J Med. 2013;369(18):1726–1734.
2.
JentzerJCVallabhajosyulaSKhannaAKChawlaLSBusseLWKashaniKB. Management of refractory vasodilatory shock. Chest. 2018;154(2):416–426. doi:10.1016/j.chest.2017.12.021.
3.
CecconiMDe BackerDAntonelliM, et al.Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med. 2014;40(12):1795–1815.
4.
RhodesAEvansLEAlhazzaniW, et al.Surviving sepsis campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304–377.
5.
AnnaneDVignonPRenaultA, et al.Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet. 2007;370(9588):676–684.
6.
AsfarPMezianiFHamelJF, et al.High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014;370(17):1583–1593.
7.
De BackerDBistonPDevriendtJ, et al.Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779–789.
8.
MyburghJAHigginsAJovanovskaALipmanJRamakrishnanNSantamariaJ. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med. 2008;34(12):2226–2234.
9.
SchmittingerCATorgersenCLucknerGSchroderDCLorenzIDunserMW. Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med. 2012;38(6):950–958.
10.
DunserMWHasibederWR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med. 2009;24(5):293–316.
11.
KanjiSWilliamsonDRYaghchiBMAlbertMMcIntyreL. Epidemiology and management of atrial fibrillation in medical and noncardiac surgical adult intensive care unit patients. J Crit Care. 2012;27(3):326.e321–e328.
12.
SviriSHashoulJStavIvan HeerdenPV. Does high-dose vasopressor therapy in medical intensive care patients indicate what we already suspect?J Crit Care. 2014;29(1):157–160.
13.
SaadAFMaybauerMO. The role of vasopressin and the vasopressin type V1a receptor agonist selepressin in septic shock. J Crit Care. 2017;40:41–45.
14.
VailEAGershengornHBHuaMWalkeyAJWunschH. Epidemiology of vasopressin use for adults with septic shock. Ann Am Thorac Soc. 2016;13(10):1760–1767.
15.
BellettiABenedettoUBiondi-ZoccaiG, et al.The effect of vasoactive drugs on mortality in patients with severe sepsis and septic shock. A network meta-analysis of randomized trials. J Crit Care. 2017;37:91–98.
16.
TrotterJ. Catecholamine-resistant hypotension following induction for spinal exploration. AANA J. 2012;80(1):55–60.
17.
LaporteRKohanAHeitzmannJ, et al.Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension. J Pharmacol Exp Ther. 2011;337(3):786–796.
18.
RussellJAVincentJLKjolbyeAL, et al.Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care. 2017;21(1):213.
19.
BoydJHForbesJNakadaTAWalleyKRRussellJA. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med. 2011;39(2):259–265.
20.
HeXSuFTacconeFS, et al.A selective V(1A) receptor agonist, selepressin, is superior to arginine vasopressin and to norepinephrine in ovine septic shock. Crit Care Med. 2016;44(1):23–31.
21.
MaybauerMOMaybauerDMEnkhbaatarP, et al.The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*. Crit Care Med. 2014;42(7): e525–e533.
22.
LangeMErtmerCRehbergS, et al.Effects of two different dosing regimens of terlipressin on organ functions in ovine endotoxemia. Inflamm Res. 2011;60(5):429–437.
23.
BlascoVLeoneMGeisslerAAntoniniFAlbaneseJMartinC. Impact of terlipressin on renal graft function. Shock. 2008;29(6):667–669.
24.
Glypressin [package insert]. New South Wales, Australia: Ferring Pharmaceuticals; 2012.
25.
MorelliAErtmerCPietropaoliPWestphalM. Terlipressin: a promising vasoactive agent in hemodynamic support of septic shock. Expert Opin Pharmacother. 2009;10(15):2569–2575.
26.
Giapreza [package insert]. San Diego, CA: La Jolla Pharmaceutical Company; 2018.
LewisRJAngusDCLaterrePF, et al.Rationale and design of an adaptive phase 2b/3 clinical trial of selepressin for adults in septic shock. Selepressin evaluation programme for sepsis-induced shock-adaptive clinical trial. Ann Am Thorac Soc. 2018;15(2):250–257.
30.
HigginsJPTGreenS, eds. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration; 2011. www.training.cochrane.org/handbook. Accessed October 28, 2018.
31.
MoherDLiberatiATetzlaffJAltmanDG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed1000097.
32.
KhannaAEnglishSWWangXS, et al.Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419–430.
33.
BusseLAlbertsonTGongM, et al.Outcomes in patients with acute respiratory distress syndrome receiving angiotensin II for vasodilatory shock. Critical Care. 2018;22(Suppl 1):P125.
34.
McCurdyMBusseLWGongMN, et al.Association of angiotensin II dose with all-cause mortality in patients with vasodilatory shock. Critical Care. 2018;22(Suppl 1):P124.
35.
SzerlipHBihoracAChangS, et al.Effect of disease severity on survival in patients receiving angiotensin II for vasodilatory shock. Crit Care Med. 2018;46:3.
36.
TumlinJAMuruganRDeaneAM, et al.Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med. 2018;46(6):949–957. doi:10.1097/CCM.0000000000003092.
37.
WunderinkRGAlbertsonTEBusseLW, et al.Baseline angiotensin levels and ACE effects in patients with vasodilatory shock treated with angiotensin II. Intensive Care Med Exp. 2017;5(Suppl 2):0703.
38.
ChawlaLSBusseLBrasha-MitchellE, et al.Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014;18(5):534.
39.
SinghSMalhotraRP. Comparative study of angiotensin and nor-adrenaline in hypotensive states (shock). J Assoc Physicians India. 1966;14(11):639–645.
40.
CohnJNLuriaMH. Studies in clinical shock and hypotension II: hemodynamic effects of norepinephrine and angiotensin. J Clin Invest. 1965;44:1494–1504.
41.
PrakashVChoudhuryAKSarinSK. Early introduction of a combination of low dose terlipressin and noradrenaline as vasopressors is superior to high dose noradrenaline alone in patients of cirrhosis with septic shock (NCT02468063). Hepatology. 2017;66:138A.
42.
ChoudhuryAKedarisettyCKVashishthaC, et al.A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock. Liver Int. 2017;37(4):552–561.
43.
XiaoXZhangJWangY, et al.Effects of terlipressin on patients with sepsis via improving tissue blood flow. J Surg Res. 2016;200(1):274–282.
44.
HuaFWangXZhuL. Terlipressin decreases vascular endothelial growth factor expression and improves oxygenation in patients with acute respiratory distress syndrome and shock. J Emerg Med. 2013;44(2):434–439.
45.
SvobodaPScheerPKantorovaI, et al.Terlipressin in the treatment of late phase catecholamine-resistant septic shock. Hepatogastroenterology. 2012;59(116):1043–1047.
46.
MorelliADonatiAErtmerC, et al.Effects of vasopressinergic receptor agonists on sublingual microcirculation in norepinephrine-dependent septic shock. Crit Care. 2011;15(5):R217.
47.
AfifiMAbedN. The effect of synthetic vasopressin in septic shock using eosphageal Doppler. Eur Heart J. 2010;12(Suppl F):P246.
48.
AcevedoJGFernandezJEscorsellAMasAGinesPArroyoV. Clinical efficacy and safety of terlipressin administration in cirrhotic patients with septic shock. J Hepatol. 2009;50:S73.
49.
MorelliAErtmerCRehbergS, et al.Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care. 2009;13(4):R130.
50.
MorelliAErtmerCLangeM, et al.Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. Br J Anaesth. 2008;100(4):494–503.
51.
AlbaneseJLeoneMDelmasAMartinC. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med. 2005;33(9):1897–1902.
52.
US Food and Drug Administration. Drugs@FDA: FDA approved drug products. United States Department of Health and Human Services. US Food and Drug Administration website. https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed October 28, 2018.
Banuelos RamirezDDSanchez AlonsoSRamirez PalmaMM. Sildenafil in severe peripheral ischemia induced by terlipressin. A case report. Reumatol Clin. 2011;7(1):59–60.
56.
BorregoRLopez-HerceJMenciaSCarrilloASanchoLBustinzaA. Severe ischemia of the lower limb and of the intestine associated with systemic vasoconstrictor therapy and femoral arterial catheterization. Pediatr Crit Care Med. 2006;7(3):267–269.
57.
Di MicoliABracciECappaFM, et al.Terlipressin infusion induces ischemia of breast skin in a cirrothic patient with hepatorenal syndrome. Dig Liver Dis. 2008;40(4):304–305.
58.
FernandesSRBaldaiaCGoncalvesAR. Genital ischemia in a patient under terlipressin therapy. GE Port J Gastroenterol. 2016;23(4):224–225.
59.
Ozel CoskunBDKaramanAGorkemHBugdayIPoyrazogluOKSenelF. Terlipressin-induced ischemic skin necrosis: a rare association. Am J Case Rep. 2014;15:476–479.
60.
AnantasitNBoydJHWalleyKRRussellJA. Serious adverse events associated with vasopressin and norepinephrine infusion in septic shock. Crit Care Med. 2014;42(8):1812–1820.
61.
WangHLiuABoWFengXHuY. Terlipressin in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(16): e0431.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
